Inrebic Capsule
NDC Package 59572-720-12
Package Information
Inrebic (fedratinib hydrochloride) capsules is a medication used to treat a certain type of cancer (myelofibrosis). This formulation utilizes a capsule delivery system. Marketed by Celgene Corporation, this product is identified by NDC 59572-720 and is authorized under FDA application NDA212327.
Identification & Billing
- RxCUI: 2197495 - fedratinib 100 MG Oral Capsule
- RxCUI: 2197495 - fedratinib (as fedratinib dihydrochloride 117.3 MG) 100 MG Oral Capsule
- RxCUI: 2197501 - INREBIC 100 MG Oral Capsule
- RxCUI: 2197501 - fedratinib 100 MG Oral Capsule [Inrebic]
- RxCUI: 2197501 - Inrebic (as fedratinib dihydrochloride monohydrate 117.3 MG) 100 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 59572 - Celgene Corporation
- 59572-720 - Inrebic
- 59572-720-12 - 120 CAPSULE in 1 BOTTLE, PLASTIC
- 59572-720 - Inrebic
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59572-720-12 identifies a specific commercial package of 120 capsule in 1 bottle, plastic of Inrebic, a human prescription drug labeled by Celgene Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 120 billable units per package. This capsule is formulated for oral use and contains fedratinib hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Celgene Corporation on August 16, 2019. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
How is this Celgene Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59572072012. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.